Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
December 07, 2022 08:05 ET
|
Esperion Therapeutics, Inc.
– Demonstrates statistically significant and clinically meaningful results – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse...
Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
April 27, 2021 08:00 ET
|
Esperion Therapeutics, Inc.
– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy –– Nearly half of trial participants are women, a...
Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid
January 09, 2017 08:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...